Jendralla H, Granzer E, von Kerekjarto B, Krause R, Schacht U, Baader E, Bartmann W, Beck G, Bergmann A, Kesseler K
Hoechst AG, Frankfurt, Germany.
J Med Chem. 1991 Oct;34(10):2962-83. doi: 10.1021/jm00114a004.
A group of 43 optically active sodium carboxylates (11a-qq and the corresponding lactones 4 were prepared from respective phenols 8 according to Schemes I-III. Phenols 8 were synthesized from commercially available compounds according to Schemes IV-IX. A number of these HMG-CoA reductase inhibitors 11 exceeded mevinolin's activity in vitro (Tables II and III). Selected lactones 4 effectively inhibited hepatic "de novo" cholesterol synthesis in rats in vivo (Table IV). After po administration to rabbits, 4ff(11ff), 4hh, and notably 11jj reduced plasma cholesterol levels more potently than mevinolin (Table V). Whereas 4ff(11ff) displayed the slight superiority expected according to in vitro data, 4hh and 11jj were considerably more potent than expected. Each of these compounds had only moderate activity after po administration to dogs (Table VI). Compound di-11ii, a hybrid of the structural elements of probucol and HMG-CoA reductase inhibitors, after po administration to rats decreased serum lipoproteins and increased HDL/LDL ratio better than probucol (Table VII). HMG-CoA reductase inhibitor 11ll and phenolic building blocks 8, notably 8jj and 8kk, inhibited LDL oxidation in vitro (Table VIII). Chemical structure-activity relationships (Table IX) and the pharmacological profile of phenoxy-type inhibitors 11 diverged from those of known HMG-CoA reductase inhibitors.
根据方案I - III,由相应的酚8制备了一组43种旋光性羧酸钠(11a - qq)以及相应的内酯4。酚8根据方案IV - IX由市售化合物合成。这些HMG - CoA还原酶抑制剂11中的许多在体外活性超过了洛伐他汀(表II和III)。所选的内酯4在体内能有效抑制大鼠肝脏的“从头”胆固醇合成(表IV)。给兔子口服给药后,4ff(11ff)、4hh,尤其是11jj比洛伐他汀更有效地降低了血浆胆固醇水平(表V)。虽然4ff(11ff)表现出根据体外数据预期的轻微优势,但4hh和11jj的效力比预期的要高得多。这些化合物在给狗口服给药后均只有中等活性(表VI)。化合物di - 11ii是普罗布考和HMG - CoA还原酶抑制剂结构元件的杂合体,给大鼠口服给药后比普罗布考更能降低血清脂蛋白并提高HDL/LDL比值(表VII)。HMG - CoA还原酶抑制剂11ll和酚类结构单元8,尤其是8jj和8kk,在体外抑制LDL氧化(表VIII)。苯氧基型抑制剂11的化学结构 - 活性关系(表IX)和药理特性与已知的HMG - CoA还原酶抑制剂不同。